Achievements
-
.Tworectal artesunate
suppository products for pre-referral management of severe malaria approved
-
.18,000health-care workers
across 2,082 health-care facilities trained to administer injectable artesunate for severe malaria
-
.Single-dosetafenoquine
for relapse prevention of P. vivax malaria approved by the US FDA
Defeating malaria together
Featured resources
-
The life-saving benefits of pre-referral management
Apr 2019 -
Plasmodium knowlesi exhibits distinct in vitro drug susceptibility profiles from those of Plasmodium falciparum
Apr 2019 -
African isolates show a high proportion of multiple copies of the Plasmodium falciparum plasmepsin-2 gene, a piperaquine resistance marker
Apr 2019
Events
-
26Jun
7th International Conference on Plasmodium vivax Research (ICPvR)
26-28 JuneParis, France -
30Jun
Gordon Research Conference - Translational Malaria Research in Patients and Populations
30 June - 5 JulyLes Diablerets, Switzerland -
03Nov
MMV's 20th Anniversary
11 November 2019Geneva, Switzerland